BioSpace News Archive

Bausch Health Companies Inc. today announced the presentation of nine posters during the Innovations in Dermatology Conference, which takes place Nov. 3-5, 2022, in Las Vegas, Nev.

Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today reported financial results and business updates for the quarter ended September 30, 2022.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2022 financial results will be released after market close on Tuesday, November 8th, 2022.

Stealth BioTherapeutics Corp today announced encouraging Phase 1 data on the safety and tolerability of SBT-272, a next-generation small molecule designed to reach therapeutic concentrations in the brain and to restore mitochondrial structure and function.

Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo ® C radiation therapy system for the Type B market has been submitted to the Chinese National Medical Products Administration (NMPA).

Avinger, Inc. today announced that it will release its financial results for the third quarter 2022 after the close of trading on Wednesday, November 9, 2022.

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting™ 2022, hosted by the American Association for the Study of Liver Diseases (AASLD), to be held November 4-8, 2022, in Washington, D.C.

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced the appointment of Colleen A. Hanlon, Ph.D. as Vice President of Medical Affairs.

Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced the appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel, effective immediately.

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced that subject screening for the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% is complete, allowing for a topline data announcement target of 2Q-2023.